Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ovarian Cancer Clinical Trials

115 recruiting trials for Ovarian Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
115
Total Trials
115
Recruiting Now
8
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06238479

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The...

Sponsor: Eli Lilly and CompanyEnrolling: 49020 locations
RECRUITINGNCT06717295

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune...

The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This...

Sponsor: Javier ToledoEnrolling: 60004 locations
RECRUITINGPhase 1NCT07424547

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

The goal of this clinical trial is to learn if investigational drug called SYS6043 works in adults with advanced or metastatic solid tumors that have spread or cannot be treated...

Sponsor: Conjupro Biotherapeutics, Inc.Enrolling: 3865 locations
RECRUITINGPhase 1NCT05104515

First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine

OVM-200 will be tested in humans for the first time in Study OVM-200-100. Up to 52 patients aged 18-75 with prostate, lung or ovarian cancer will be enrolled in the Study to find...

Sponsor: Oxford Vacmedix UK Ltd.Enrolling: 364 locations
RECRUITINGNCT05366881

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer...

Sponsor: Adela, IncEnrolling: 700017 locations
RECRUITINGNCT05349227

Comprehensive Outcomes for After Cancer Health

This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary...

Sponsor: Pack HealthEnrolling: 6257 locations
RECRUITINGPhase 1 / Phase 2NCT06799637

Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...

Sponsor: Evopoint Biosciences Inc.Enrolling: 20020 locations
RECRUITINGNCT03452774

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool,...

Sponsor: Massive Bio, Inc.Enrolling: 5000020 locations
RECRUITINGNCT06167135

Polycystic Ovary Syndrome, Mitochondrial Dysfunction, Obesity, Insulin Resistance Infertility (POMODORI) Cohort

Enrolling of 150 female patients of fertile age diagnosed with PCOS, insulin resistance, infertility, or mitochondrial disease, and the same number of age- and sex-matched...

Sponsor: Semmelweis UniversityEnrolling: 1501 location
RECRUITINGNCT05973175

REFUEL PCOS Study 1

Polycystic Ovary Syndrome (PCOS) affects 10% of all women, and it usually co-exists with high levels of male pattern hormones (also termed androgens). Women with PCOS are at...

Sponsor: Royal College of Surgeons, IrelandEnrolling: 401 location
RECRUITINGEarly Phase 1NCT07403201

The Effect of Therapy Combination in PCOS With Dlbs 3233

The effect of combination therapy dlbs 3233 and clomifen citrate vs clomifen citrate on homa ir, maturation follicle, and menstrual cycle in PCOS cases at Muhammadiyah Asri...

Sponsor: InlacinpenelitianEnrolling: 901 location
RECRUITINGPhase 2NCT05887609

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian...

Sponsor: University of Colorado, DenverEnrolling: 535 locations
RECRUITINGPhase 2NCT06815497

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens...

Sponsor: Tyler J CurielEnrolling: 332 locations
RECRUITINGPhase 2NCT05903807

[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer

Fifty (n=50) patients with newly diagnosed ovarian cancer will undergo FAPI PET/CTs in addition to routine diagnostic workup (including FDG PET/CT) at primary staging and...

Sponsor: Aalborg University HospitalEnrolling: 501 location
RECRUITINGNCT03841981

Body Fat as Determinant of Female Gonadal Dysfunction

Reproduction requires from women enough energy depots to warrant an adequate nutritional supply to the fetus. Hence, adipose tissue is able to communicate with female...

Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalEnrolling: 501 location
RECRUITINGPhase 2NCT04469764

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back...

Sponsor: Jonsson Comprehensive Cancer CenterEnrolling: 321 location
RECRUITINGPhase 3NCT06476184

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With...

SALVOVAR will be a pragmatic open-label multicenter randomized phase III trial (ratio 1:1) comparing the efficacy of the salvage weekly dose-dense regimen with those of the...

Sponsor: ARCAGY/ GINECO GROUPEnrolling: 25020 locations
RECRUITINGNCT02296307

DOvEE - Diagnosing Ovarian & Endometrial Cancer Early

This study hopes to improve early detection of ovarian and endometrial cancers. It will determine if women with bloating, abdominal distension, abdominal/pelvic pain, increased...

Sponsor: McGill UniversityEnrolling: 136008 locations
RECRUITINGNCT06422455

Access to Genetic Testing in Underserved Patients With Cancer

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human...

Sponsor: University of Southern CaliforniaEnrolling: 8002 locations
RECRUITINGPhase 2NCT06890858

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

This is a prospective study investigating whether the research on Fasudil Hydrochloride in the treatment of gene-specific ovarian cancer can be applied to predict sensitivity to...

Sponsor: Zhejiang Provincial People's HospitalEnrolling: 201 location
RECRUITINGPhase 2NCT05983276

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and...

Sponsor: Loyola UniversityEnrolling: 401 location
RECRUITINGPhase 3NCT06994195

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent...

This trial is a registered, phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with platinum-resistant recurrent...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 3841 location
RECRUITINGNCT01601171

Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate

The purpose of this study is to explore the genetic basis of reproductive disorders and cleft lip and/or palate.

Sponsor: Centre Hospitalier Universitaire VaudoisEnrolling: 20001 location
RECRUITINGPhase 1 / Phase 2NCT05920798

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

This phase I/II trial tests the safety, side effects, best dose, and effectiveness of multi-epitope folate receptor alpha-loaded dendritic cell vaccine (FRalphaDC) with...

Sponsor: Mayo ClinicEnrolling: 403 locations
RECRUITINGNCT06553612

Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive...

This project proposes a structuring of supportive oncology care for the recovery phase after gynecological cancer (ovarian/trope/peritoneum or endometrium). Patients will be...

Sponsor: Centre Francois BaclesseEnrolling: 26813 locations
RECRUITINGPhase 1NCT05969041

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial...

Sponsor: Myeloid TherapeuticsEnrolling: 486 locations
RECRUITINGNCT07129434

Strengthening Healthy Emotional Co-regulation of Mothers With PCOS and Obesity and Their Infants

It is both timely and important to invest in interventions that can improve healthy emotional co-regulation. It is proposed to evaluate the feasibility and limited efficacy of an...

Sponsor: Oulu University HospitalEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT06888921

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian...

Sponsor: Compugen LtdEnrolling: 6020 locations
RECRUITINGPhase 1NCT03049462

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor...

Background: Brown adipose tissue (BAT) is a type of fat in the body. It may prevent weight gain, improve insulin sensitivity, and reduce fatty liver. Researchers want to see if...

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling: 1001 location
RECRUITINGNCT05833321

Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological...

Sponsor: Centre Hospitalier Metropole SavoieEnrolling: 751 location
RECRUITINGNCT03976999

Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical datas to improve knowledge about cancer and help to...

Sponsor: Institut du Cancer de Montpellier - Val d'AurelleEnrolling: 3001 location
RECRUITINGPhase 2NCT06541314

Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

This study is an interventional, single-arm, open-label clinical trial. To evaluate the safety and efficacy of Fluzoparib as neoadjuvant therapy in patients with FIGO stage III...

Sponsor: Qilu Hospital of Shandong UniversityEnrolling: 481 location
RECRUITINGNCT06324175

Spatial Radiogenomics of Ovarian Cancer

The biological spatial and temporal heterogeneity of High Grade Serous Ovarian Carcinoma (HGSOC) severely impacts the effectiveness of therapies and is a determinant of poor...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 241 location
RECRUITINGPhase 2NCT05113368

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

To see how effective the study medicine combined with hormone therapy is when given to participants with recurrent low-grade serous ovarian cancer.

Sponsor: Sarah K. Lynam MDEnrolling: 311 location
RECRUITINGNCT07231510

Chlordecone Exposure and Female Fertility

Chlordecone is an organochlorine pesticide used in the French West Indies (FWI) from 1972 to 1993 to control the banana root borer. Due to its very long persistence the population...

Sponsor: Centre Hospitalier Universitaire de la GuadeloupeEnrolling: 6341 location
RECRUITINGPhase 3NCT05804370

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial...

Sponsor: NX Development CorpEnrolling: 1706 locations
RECRUITINGPhase 2NCT06540729

RC48 in Combination With AK104 and Bevacizumab in OCCC

Disitamab vedotin (RC48) in combination with AK104 (PD-1/CTLA-4 bispecific) and bevacizumab for the treatment of recurrent and persistent clear cell ovarian cancer: a single-arm,...

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityEnrolling: 391 location
RECRUITINGPhase 3NCT06824467

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard...

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan...

Sponsor: Merck Sharp & Dohme LLCEnrolling: 77020 locations
RECRUITINGPhase 2NCT07059845

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous...

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events...

Sponsor: AbbVieEnrolling: 32010 locations
RECRUITINGPhase 2NCT07311577

Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing,...

This is a prospective, multicenter, phase II study designed to evaluate the efficacy and safety of disitamab vedotin combined with platinum plus bevacizumab as first-line therapy...

Sponsor: Jiangsu Cancer Institute & HospitalEnrolling: 432 locations
RECRUITINGNCT06902467

Combined Intraperitoneal Chemotherapy Regimen After Optimal Interval Surgery in Advanced Ovarian Cancer: BICOV-1...

A multicenter, low-intervention, drug-based study to evaluate the feasibility and safety of a combined regimen of two intraperitoneal chemotherapy modalities (used in routine...

Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaEnrolling: 201 location
RECRUITINGPhase 2NCT07182526

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With...

This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and...

Sponsor: Al-Mustansiriyah UniversityEnrolling: 1501 location
RECRUITINGPhase 1 / Phase 2NCT05803018

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including...

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.Enrolling: 381 location
RECRUITINGPhase 2NCT04606914

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant...

The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy...

Sponsor: University of Alabama at BirminghamEnrolling: 709 locations
RECRUITINGNCT07259304

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

This study assesses how personal relationships (such as friendships, family relationships, or romantic partners) influence the physical activity (exercise) and well-being of young...

Sponsor: University of Southern CaliforniaEnrolling: 2501 location
RECRUITINGPhase 1NCT04633239

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to...

Sponsor: National Cancer Institute (NCI)Enrolling: 4220 locations
RECRUITINGPhase 1 / Phase 2NCT05551507

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects...

Sponsor: InxMed (Shanghai) Co., Ltd.Enrolling: 1507 locations
RECRUITINGPhase 3NCT05255471

MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in...

MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based...

Sponsor: National Cancer Institute, NaplesEnrolling: 2001 location
RECRUITINGNCT07102797

ActiveGirls: Physical Activity, Hormone Health, and Diabetes Risk in Early Adolescence

This study explores how a physical activity program can affect hormone health and diabetes risk in girls ages 8-12 who may be at higher risk. The study aims to address: * Does...

Sponsor: Massachusetts General HospitalEnrolling: 401 location
RECRUITINGPhase 1 / Phase 2NCT05735080

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human...

Sponsor: Incyclix BioEnrolling: 15018 locations

Showing 50 of 115 trials.Search all Ovarian Cancer trials

Frequently Asked Questions

There are currently 115 clinical trials for Ovarian Cancer, with 115 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ovarian Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 8 Phase 3 trials for Ovarian Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice — always talk to your doctor about clinical trial participation.